Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients

Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients

MT newswireMT newswire2026/08/25 11:41
07:41 AM EDT, 08/25/2026 (MT Newswires) -- Veeva Systems (VEEV) has signed Biogen (BIIB) and Regeneron Pharmaceuticals (REGN) as new users for its Veeva Vault CRM platform, according to Tuesday statements from Veeva. No financial details were disclosed. Biogen will use Veeva Vault CRM as its agentic commercial foundation to deliver drugs to patients, while Regeneron plans to use the platform to generate commercial evidence that will back treatment adoption, Veeva said.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD

Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.

智通财经2026/09/21 07:16

Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).

智通财经2026/09/21 07:11

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11